Document is current
Any future updates will be listed below
-
Authors
Rodgers, Buel D. https://orcid.org/0000-0003-0751-1105
Ward, Christopher W.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R44CA221539)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R43AR075438)
- License Information
-
More Information
Article History
Received: 5 May 2025
Revised: 13 October 2025
Accepted: 13 November 2025
First Online: 25 November 2025
Competing interests
: BDR is the majority owner, Founder and CEO of Aavogen, which is developing AVGN7.2 for the treatment of different myopathies, muscular dystrophies and other muscle wasting disorders. CWW is the Co-founder and CSO of Myologica LLC, a privately owned contract research organization that performed many of the studies reported herein.
: Animal experiments were performed by Myologica LLC in leased vivarium and laboratory space at the University of Maryland Baltimore. Mice were housed in environmentally controlled rooms and provided food and water ad libitum . Housing and use were conducted in accordance to animal use protocols preapproved by the university’s institutional animal care and use committee and according to National Institutes of Health guidelines.
